299 related articles for article (PubMed ID: 26555944)
1. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
Sautenet B; Blancho G; Büchler M; Morelon E; Toupance O; Barrou B; Ducloux D; Chatelet V; Moulin B; Freguin C; Hazzan M; Lang P; Legendre C; Merville P; Mourad G; Mousson C; Pouteil-Noble C; Purgus R; Rerolle JP; Sayegh J; Westeel PF; Zaoui P; Boivin H; Le Gouge A; Lebranchu Y
Transplantation; 2016 Feb; 100(2):391-9. PubMed ID: 26555944
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
[TBL] [Abstract][Full Text] [Related]
5. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
[TBL] [Abstract][Full Text] [Related]
6. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
7. An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation.
Bailly E; Ville S; Blancho G; Morelon E; Bamoulid J; Caillard S; Chatelet V; Malvezzi P; Tourret J; Vuiblet V; Anglicheau D; Bertrand D; Grimbert P; Haidar F; Hazzan M; Kamar N; Merville P; Mousson C; Pernin V; Pouteil-Noble C; Purgus R; Sayegh J; Westeel PF; Sautenet B; Gatault P; Büchler M
Transpl Int; 2020 Jul; 33(7):786-795. PubMed ID: 32279367
[TBL] [Abstract][Full Text] [Related]
8. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
[TBL] [Abstract][Full Text] [Related]
10. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
[TBL] [Abstract][Full Text] [Related]
11. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
13. Development of antibody mediated rejection shortly after acute cellular rejection in a pediatric kidney transplantation recipient.
Okada M; Kamei K; Matsuoka K; Ito S
CEN Case Rep; 2018 Nov; 7(2):288-291. PubMed ID: 29949115
[TBL] [Abstract][Full Text] [Related]
14. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes.
Garrouste C; Canaud G; Büchler M; Rivalan J; Colosio C; Martinez F; Aniort J; Dudreuilh C; Pereira B; Caillard S; Philipponnet C; Anglicheau D; Heng AE
Transplantation; 2017 Mar; 101(3):649-656. PubMed ID: 27043407
[TBL] [Abstract][Full Text] [Related]
16. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
[TBL] [Abstract][Full Text] [Related]
17. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
[TBL] [Abstract][Full Text] [Related]
19. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
Woodle ES; First MR; Pirsch J; Shihab F; Gaber AO; Van Veldhuisen P;
Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]